• Search
      • Search Interactions Search Categories
    • Browse
      • Browse Categories Browse Sources
    • Information
      • About Publications Interaction Types & Directionalities Interaction Score & Query Score API Documentation FAQ Known Data Clients News Contact
    • Downloads
      • Data Source Code

NEVIRAPINE Drug Record

  • Summary
  • Interactions
  • Claims
  • NEVIRAPINE chembl:CHEMBL57 Approved

    Alternate Names:

    BIRG-0587
    NEVIRAPINE ANHYDROUS
    VIRAMUNE
    NSC-641530
    VIRAMUNE XR
    NEVIRAPINE
    2',3'-E)(1,4)DIAZEPIN-6-ONE
    11-CYCLOPROPYL-5,11-DIHYDRO-4-METHYL-6H-DIPYRIDO(3,2-B
    11-CYCLOPROPYL-5,11-DIHYDRO-4-METHYL-6H-DIPYRIDO(3,2-B:2',3'-E)(1,4)DIAZEPIN-6-ONE
    NVP
    NEV
    rxcui:53654
    chemidplus:129618-40-2
    pubchem.compound:4463
    drugbank:00238
    chembl:CHEMBL57

    Drug Info:

    (1 More Sources)

    Publications:

    Weiss J et al., 2007, Inhibition of MRP1/ABCC1, MRP2/ABCC2, and MRP3/ABCC3 by nucleoside, nucleotide, and non-nucleoside reverse transcriptase inhibitors., Drug Metab Dispos
    Sakatis MZ et al., 2012, Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds., Chem Res Toxicol
    Lehr T et al., 2011, Integration of absorption, distribution, metabolism, and elimination genotyping data into a population pharmacokinetic analysis of nevirapine., Pharmacogenet Genomics
    Chantarangsu S et al., 2011, Genome-wide association study identifies variations in 6p21.3 associated with nevirapine-induced rash., Clin Infect Dis
    Ciccacci C et al., 2010, Nevirapine-induced hepatotoxicity and pharmacogenetics: a retrospective study in a population from Mozambique., Pharmacogenomics
    Haas DW et al., 2006, Pharmacogenetics of nevirapine-associated hepatotoxicity: an Adult AIDS Clinical Trials Group collaboration., Clin Infect Dis
    Ritchie MD et al., 2006, Drug transporter and metabolizing enzyme gene variants and nonnucleoside reverse-transcriptase inhibitor hepatotoxicity., Clin Infect Dis
    Zembruski NC et al., 2011, Interaction potential of etravirine with drug transporters assessed in vitro., Antimicrob Agents Chemother
    Gozalo C et al., 2011, Pharmacogenetics of toxicity, plasma trough concentration and treatment outcome with nevirapine-containing regimen in anti-retroviral-naïve HIV-infected adults: an exploratory study of the TRIANON ANRS 081 trial., Basic Clin Pharmacol Toxicol
    Mahungu T et al., 2009, Cytochrome P450 2B6 516G-->T is associated with plasma concentrations of nevirapine at both 200 mg twice daily and 400 mg once daily in an ethnically diverse population., HIV Med
    Petit et al., 2003, Increased VLDL-apoB and IDL-apoB production rates in nonlipodystrophic HIV-infected patients on a protease inhibitor-containing regimen: a stable isotope kinetic study., J. Lipid Res.
    Borgiani P et al., 2014, HCP5 genetic variant (RS3099844) contributes to Nevirapine-induced Stevens Johnsons Syndrome/Toxic Epidermal Necrolysis susceptibility in a population from Mozambique., Eur J Clin Pharmacol
    Ciccacci C et al., 2017, Impact of glutathione transferases genes polymorphisms in nevirapine adverse reactions: a possible role for GSTM1 in SJS/TEN susceptibility., Eur J Clin Pharmacol
    Olagunju A et al., 2016, Pregnancy affects nevirapine pharmacokinetics: evidence from a CYP2B6 genotype-guided observational study., Pharmacogenet Genomics
    Ciccacci C et al., 2013, Association between CYP2B6 polymorphisms and Nevirapine-induced SJS/TEN: a pharmacogenetics study., Eur J Clin Pharmacol
    Heil SG et al., 2012, Associations between ABCB1, CYP2A6, CYP2B6, CYP2D6, and CYP3A5 alleles in relation to efavirenz and nevirapine pharmacokinetics in HIV-infected individuals., Ther Drug Monit
    Yuan J et al., 2011, Toxicogenomics of nevirapine-associated cutaneous and hepatic adverse events among populations of African, Asian, and European descent., AIDS
    Chen J et al., 2010, CYP2B6 polymorphism and nonnucleoside reverse transcriptase inhibitor plasma concentrations in Chinese HIV-infected patients., Ther Drug Monit
    Rotger M et al., 2005, Influence of CYP2B6 polymorphism on plasma and intracellular concentrations and toxicity of efavirenz and nevirapine in HIV-infected patients., Pharmacogenet Genomics
    Lang T et al., 2001, Extensive genetic polymorphism in the human CYP2B6 gene with impact on expression and function in human liver., Pharmacogenetics
    Zanger UM et al., 2007, Polymorphic CYP2B6: molecular mechanisms and emerging clinical significance., Pharmacogenomics
    Faucette et al., 2007, Relative activation of human pregnane X receptor versus constitutive androstane receptor defines distinct classes of CYP2B6 and CYP3A4 inducers., J. Pharmacol. Exp. Ther.
    Petit et al., 2004, Serum adiponectin and metabolic parameters in HIV-1-infected patients after substitution of nevirapine for protease inhibitors., Eur. J. Clin. Invest.
    Liptrott NJ et al., 2012, Association of ABCC10 polymorphisms with nevirapine plasma concentrations in the German Competence Network for HIV/AIDS., Pharmacogenet Genomics
  • NEVIRAPINE   CCHCR1

    Interaction Score: 5.38

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    21810746


    Sources:
    PharmGKB

  • NEVIRAPINE   TCF19

    Interaction Score: 5.38

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    21810746


    Sources:
    PharmGKB

  • NEVIRAPINE   POLR3G

    Interaction Score: 5.38

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    21810746


    Sources:
    PharmGKB

  • NEVIRAPINE   CYCSP5

    Interaction Score: 4.03

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    28689274 24322967


    Sources:
    PharmGKB

  • NEVIRAPINE   TRAF3IP2

    Interaction Score: 2.69

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    PharmGKB

  • NEVIRAPINE   HCP5

    Interaction Score: 1.79

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    24322967


    Sources:
    PharmGKB

  • NEVIRAPINE   ABCC10

    Interaction Score: 1.34

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    22082652


    Sources:
    PharmGKB

  • NEVIRAPINE   ADIPOQ

    Interaction Score: 1.08

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    15305892


    Sources:
    NCI

  • NEVIRAPINE   CYP2B6

    Interaction Score: 0.9

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    28689274 27195527 23774940 22354160 21860339 21824325 21505298 20625352 20017669 19228205 15864119 11470993 17638512 17041008


    Sources:
    NCI PharmGKB

  • NEVIRAPINE   APOB

    Interaction Score: 0.3

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    12869587


    Sources:
    NCI

  • NEVIRAPINE   HLA-DQB1

    Interaction Score: 0.22

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    PharmGKB

  • NEVIRAPINE   ABCC3

    Interaction Score: 0.22

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    17172311


    Sources:
    DTC

  • NEVIRAPINE   ABCC1

    Interaction Score: 0.11

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    17172311


    Sources:
    DTC

  • NEVIRAPINE   CYP3A5

    Interaction Score: 0.1

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    21824325 20017669 19228205


    Sources:
    PharmGKB

  • NEVIRAPINE   ABCC2

    Interaction Score: 0.1

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    17172311


    Sources:
    DTC

  • NEVIRAPINE   ABCG2

    Interaction Score: 0.09

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    21189339


    Sources:
    DTC

  • NEVIRAPINE   ABCB1

    Interaction Score: 0.07

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    20017669 16912957 16912956 21189339


    Sources:
    DTC PharmGKB

  • NEVIRAPINE   NR1I2

    Interaction Score: 0.02

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    PharmGKB

  • NEVIRAPINE   CYP2C19

    Interaction Score: 0.02

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    21860339 22931300


    Sources:
    DTC PharmGKB

  • NEVIRAPINE   CYP2C9

    Interaction Score: 0.02

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    22931300


    Sources:
    DTC PharmGKB

  • NEVIRAPINE   CYP2D6

    Interaction Score: 0.01

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    22931300


    Sources:
    DTC PharmGKB

  • NEVIRAPINE   CYP1A2

    Interaction Score: 0.01

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    22931300


    Sources:
    DTC

  • NEVIRAPINE   CYP3A4

    Interaction Score: 0.01

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    22931300


    Sources:
    DTC PharmGKB

  • NCI: NEVIRAPINE

    • Version: 14-September-2017

    Alternate Names:
    C29277 NCI drug code

    Drug Info:

    Publications:
    Faucette et al., 2007, Relative activation of human pregnane X receptor versus constitutive androstane receptor defines distinct classes of CYP2B6 and CYP3A4 inducers., J. Pharmacol. Exp. Ther.
    Petit et al., 2004, Serum adiponectin and metabolic parameters in HIV-1-infected patients after substitution of nevirapine for protease inhibitors., Eur. J. Clin. Invest.
    Petit et al., 2003, Increased VLDL-apoB and IDL-apoB production rates in nonlipodystrophic HIV-infected patients on a protease inhibitor-containing regimen: a stable isotope kinetic study., J. Lipid Res.

  • DTC: NEVIRAPINE

    • Version: 02-September-2020

    Alternate Names:
    CHEMBL57 ChEMBL Drug ID

    Drug Info:

    Publications:
    Weiss J et al., 2007, Inhibition of MRP1/ABCC1, MRP2/ABCC2, and MRP3/ABCC3 by nucleoside, nucleotide, and non-nucleoside reverse transcriptase inhibitors., Drug Metab Dispos
    Sakatis MZ et al., 2012, Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds., Chem Res Toxicol
    Zembruski NC et al., 2011, Interaction potential of etravirine with drug transporters assessed in vitro., Antimicrob Agents Chemother

  • PharmGKB: nevirapine

    • Version: 18-August-2020

    Alternate Names:

    Drug Info:

    Publications:
    Ciccacci C et al., 2010, Nevirapine-induced hepatotoxicity and pharmacogenetics: a retrospective study in a population from Mozambique., Pharmacogenomics
    Haas DW et al., 2006, Pharmacogenetics of nevirapine-associated hepatotoxicity: an Adult AIDS Clinical Trials Group collaboration., Clin Infect Dis
    Ritchie MD et al., 2006, Drug transporter and metabolizing enzyme gene variants and nonnucleoside reverse-transcriptase inhibitor hepatotoxicity., Clin Infect Dis

  • TTD: Nevirapine

    • Version: 2020.06.01

    Alternate Names:
    D0O2EM TTD Drug ID

    Drug Info:

    Publications:

  • ChemblDrugs: chembl:CHEMBL57

    • Version: ChEMBL_27

    Alternate Names:

    Drug Info:

    Publications:

Disclaimer: This resource is intended for purely research purposes. It should not be used for emergencies or medical or professional advice.

A finding of a drug-gene interaction or potentially druggable category does not necessarily indicate effectiveness (or lack thereof) of any drug or treatment regimen. A finding of no interaction or no potentially druggable category does not necessarily indicate lack of effectiveness of any drug or treatment regimen. Drug-gene interactions or potentially druggable categories are not presented in ranked order of potential or predicted efficacy.

The dgidb.org website does not provide any medical or healthcare products, services or advice, and is not for medical emergencies or urgent situations. IF YOU THINK YOU MAY HAVE A MEDICAL EMERGENCY, CALL YOUR DOCTOR OR 911 IMMEDIATELY. Information contained on this website is not a substitute for a doctor's medical judgment or advice. We recommend that you discuss your specific, individual health concerns with your doctor or health care professional.

DGIdb (v4.2.0 - sha1 afd9f30b) • Last updated 2020-10-21